JONATHAN G. DRACHMAN - 24 Aug 2021 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Role
President and CEO, Director
Signature
/s/ Robert Ho, as Attorney-in-Fact for Jonathan Drachman
Issuer symbol
NGNE
Transactions as of
24 Aug 2021
Net transactions value
+$933,550
Form type
4
Filing time
26 Aug 2021, 19:08:27 UTC
Previous filing
05 Aug 2021
Next filing
10 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NLTX Common Stock Purchase $611,100 +100,000 +4.4% $6.11 2,348,686 24 Aug 2021 Direct F1
transaction NLTX Common Stock Purchase $161,225 +25,000 $6.45* 25,000 25 Aug 2021 See footnote F2, F3
transaction NLTX Common Stock Purchase $161,225 +25,000 $6.45* 25,000 25 Aug 2021 See footnote F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average purchase price. The lowest price at which shares were purchased was $6.1099 and the highest price at which shares were purchased was $6.1482. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2 Represents the weighted average purchase price. The lowest price at which shares were purchased was $6.09 and the highest price at which shares were purchased was $6.60.
F3 These securities are held by a spousal limited access trust of which the Reporting Person is the primary beneficiary.
F4 These securities are held by a spousal limited access trust of which the Reporting Person's spouse is the primary beneficiary.